XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration Agreement - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 31, 2020
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 17, 2021
Jun. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Revenue from collaborative arrangement   $ 1,657 $ 2,114 $ 2,679 $ 5,646      
License And Research Collaboration Agreement | Merck                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Upfront payments received $ 15,000              
Collaborative arrangement, milestone payments receivable             $ 5,000  
Deferred revenue additions 15,000     2,600   $ 5,000    
Deferred revenue   2,400   2,400        
License And Research Collaboration Agreement | Merck | Maximum [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Revenue from collaborative arrangement   $ 100   $ 100        
License And Research Collaboration Agreement | Merck | Class C Preferred Units                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Stock price per share               $ 4.0008
License And Research Collaboration Agreement | Merck | Research and Development | Maximum [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Collaborative arrangement, milestone payments receivable 280,000              
License And Research Collaboration Agreement | Merck | Sales Based | Maximum [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Collaborative arrangement, milestone payments receivable $ 250,000